Efficacy and safety of durvalumab + chemotherapy <i>vs</i>. atezolizumab + chemotherapy in the treatment of small‑cell lung cancer: a retrospective comparative cohort study.

J Thorac Dis · 2023 · PMC10323594 · PMID 37426159

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Consistent with previous findings, among patients who received durvalumab plus chemotherapy, patients without BM had a longer PFS (P=0.03), patients without BM were also found to benefit from long-term survival, but this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.